This site is intended for health professionals only

Friday 18 October 2019
LatestNews
Share |

Latest News

UK AI first to help nearly half a million with chronic conditions

Thursday 17th October 2019
A digital social enterprise and four UK health charities are coming together to harness the power of artificial intelligence (AI) to create the UK’s first AI coaching tool of its kind to support long-term health conditions.
 
Reason Digital is teaming up with Parkinson’s UK, the Stroke Association, Muscular Dystrophy UK and the MS Society to develop the project, which is set to transform the way medical advice and information is...
Thu, 17 Oct 2019
Gut itch receptors could offer a new way of targeting the underlying cause of gut pain, rather than using traditional drugs
Thu, 17 Oct 2019
The latest study, published in PLOS ONE, is the first to investigate the use of the technique in a large local cohort of people previously diagnosed with knee OA. The results show that the technique can distinguish between healthy and OA knees, and that it works well both in general practice and hospital settings
Wed, 16 Oct 2019
Initial studies established that collagen was key to keeping breast and pancreatic cancers stiff and inaccessible to treatments. In contrast, tumours arising from the nervous system were relatively soft and lacking in collagen
Wed, 16 Oct 2019
The collaborative study was funded by the National Institute for Health Research (NIHR), and a team from the Universities of Sheffield, Warwick, Birmingham and Queen Mary University in London, together with the Mental Health Foundation have published a new policy briefing into its findings
Wed, 16 Oct 2019
Overall, results from ETNA-AF at one year showed low rates of bleeding (major and gastrointestinal), intracranial haemorrhage and ischaemic events during the first year of edoxaban therapy
Tue, 15 Oct 2019
Aneurysms are often called a silent killer, because patients can display no symptoms until the aneurysm bursts. Around 80% of all patients with a ruptured aneurysm die from the condition
Tue, 15 Oct 2019
The results of two extension studies confirm the long-term safety of tildrakizumab and show high and durable PASI and PGA response rates